Benign prostatic hypertrophy affects the endothelin receptor density in the human urinary bladder and prostate

Area of Science:

• Urology
• Endocrinology
• Molecular Biology

Background:

• Benign prostatic hypertrophy (BPH) is a common condition affecting the lower urinary tract.
• Endothelin (ET) peptides and their receptors are implicated in various physiological processes, including smooth muscle function.
• Understanding ET receptor dynamics in BPH is crucial for elucidating disease mechanisms.

Purpose of the Study:

• To investigate the impact of BPH on endothelin receptor density in human bladder and prostate tissues.
• To determine the distribution and affinity of ET receptor isoforms in hypertrophic versus non-hypertrophic tissues.

Main Methods:

• Radioligand binding techniques were employed to quantify ET receptor binding sites.
• Saturation experiments and autoradiography were used to assess receptor density and localization.
• Comparison of receptor characteristics between patients with and without prostate hypertrophy (PH) and non-hypertroxy (NPH).

Main Results:

• Significant binding sites for ET isoforms (ET-1, -2, -3) were found in human bladder and prostate tissues.
• ET-1 receptors were localized in both stromal and glandular tissues of hypertrophic adenoma.
• While dissociation constants (KD) remained similar, maximal binding capacities (Bmax) for ET-1, -2, and -3 decreased in the bladder dome but increased in the adenoma of PH patients.

Conclusions:

• Benign prostatic hypertrophy significantly affects endothelin receptor density in both the bladder and prostate.
• These findings indicate a role for endothelin peptides in the pathophysiology of BPH.
• Further research into ET signaling pathways may offer therapeutic targets for BPH management.